Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

APG777

Other · developed by Apogee Therapeutics

Phase 2 Most advanced trial
APGE Developer
1 Registered trials

What is APG777?

APG777 is an investigational drug studied in Atopic Dermatitis.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Apogee Therapeutics, Inc. (APGE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
QGU9EYX5RE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06395948 Phase 2 Atopic Dermatitis Active not recruiting APGE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

More from Apogee Therapeutics

APG990 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the APGE page.

Follow APGE, the company behind APG777

See APGE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APGE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.